INTRODUCTION
Cervical cancer is an important health problem 530 000 cases seen worldwide every year and 275 000 people die consequently. It is the third most common cancer after breast and large intestine cancer in women. 1 According to data from the Ministry of health-Turkey public health department, cervical cancer is ranked at the 9th among women's cancer cases for all age groups in Turkey with a rate of 2.4%. 2 The Bethesta System (TBS) used in cytological interpretation is based on internationally accepted terminology and morphological evidence. The system is linked to the biology and management of the disease and is concise and practical. It is flexible enough to be adopted in different geographical and laboratory environments. It is suitable to change and improve with the increase of knowledge and experience. 3 In spite of all these features, the inhibition continues due to the sensitivity especially for some diagnostic categories, and the intra-observer repeatable and inter observer compliance is less than ideal. 4, 5 Any decline in sensitivity and specificity depends on human performance and can be avoided by taking appropriate preventive measures. As clinical cytologists, attention has been drawn to the risk of falling in susceptibility to PAP testing due to unfamiliarity with abnormal cells and to the decreased specificity where the fear of missing important diseases may lead to overloading of benign abnormalities. 6 The discovery of a strong association between human papilloma virus (HPV) infection and cervical cancer has changed perspectives on cervical cancer prevention by accelerating the development of protective vaccines with HPV DNA and RNA tests. Specifically developed DNAbased HPV molecular tests do not distinguish between transient and persistent infection. It alone is not as specific as the primary screening method for the detection of significant lesions. At the same time, HPV testing is ordinarily expensive and is therefore not easily accessible to anyone who can benefit from it. Therefore, additional markers are needed to improve routine clinical practice. 7 Immunocytochemical (ICC) detection of molecular changes caused by HPV in host cells can be used additionally in cytological interpretation by improving sensitivity (SE) without compromising potentially specificity (SP). For this purpose, the cyclin-dependent kinase inhibitor p16 (p16INK4a) and Ki-67 proliferation marker (MIB-1) have been investigated as additional molecular markers for cervical lesions and have been reported to be useful as an adjunct to increase the specific sensitivity of HPV testing as well as cytological screening. However, clear methodological standards are required for optimal performance in the ICC in the clinical setting. 7 Clinical guidelines recommend a routine HPV test (cotest) in conjunction with cytology for cervical cancer screening program in women over 30 years of age. It is stated that screening interval is safe every 3 years for women with normal cellular morphology and negative for HPV DNA test. It is also indicated that to estimate the feasibility and reliability of test guidelines, routine clinical practice is required. 8, 9 In our study, we analyzed the results of liquid-based cytology (LBC) of patients who applied to Eskisehir State Hospital (EDH) gynecology clinic for four years retrospectively. We compared the results of SE, SP values and histologic diagnosis cytological, HPV DNA and ICC HPV Ab results. We discussed the contribution of the ICC HPV Ab results to the cytological evaluation.
METHODS
This study included LBC test results from patients admitted to the gynecology clinic of the hospital between 2014 and 2017. HPV DNA results of the patients and pathological diagnoses of the cervical biopsy specimens were obtained from the electronic records of EDH and Eskişehir Osmangazi University (ESOGÜ) Medical Faculty Hospital Pathology Departments. The Ultra Vision Quanto Detection System was modified for ICC staining and HPVAb3 (clone K1H8) was used as primer antibody. In cases with epithelial cell atypia, a new smear was made from the remaining LBC specimen of cellular evaluation and was air-dried. Deparaffinization, hydration prior to staining and antigen retrieval steps in the manufacturer's procedure were not applied. 
RESULTS
A total of 19403 tests were evaluated in our study. The 998 test consisted of repeat samples and was excluded from the study. The first evaluation result of 925 of these tests was benign and secondary smear was taken for routine control purposes. Epithelial atypia was detected in 17 of these smears atypical squamous cells of undetermined significance (ASCUS: 15 (1.6%), lowgrade squamous intraepithelial lesion (LSIL): 1 (0.1%), high grade squamous intraepithelial lesion (HSIL): 1 (0.1%). In 68 cases that were diagnosed as ASCUS in the initial evaluation, reported as 58 were benign and 10 were LSIL in follow-up smear. The results were the same as the first outcome in the follow-up smear of 4case where LSIL was detected and 1 cases of HSIL were detected.
18404 test results were included in the study. The epithelial cell atypia ratio (positivity) was 3.4%, with ASCUS: 1.9%, ASC-H: 0.2%, LSIL: 0.9%, HSIL: 0.1%, AGS: 0.3%, Ca: 2 (0.01%) ( Table 1) . Among the 392 cases with cervical biopsy, 70.2% were diagnosed as benign, 19.6% were CIN I (LSIL), 7.7% were CIN II-III (HSIL) and 2.6% were diagnosed as carcinoma. The cross-distribution of cytological results and biopsy diagnoses is shown in Table 2 . There was a significant correlation between cytology and histology results (p<0.05). Sensitivity and specificity rates were obtained as 72.09%-91.28% for LSIL and 73.33-100% for HSIL, respectively. Among HPV-DNA results of 55 patients, 52.7% were negative, and 47.3% were positive. Biopsy diagnosis of 28 of these patients was attained (14 benign, 10 LSIL and 4 HSIL) ( Table 3 ). The correlation between HPV DNA and biopsy results was statistically significant (K=0.068). According to biopsy results, SE and SP values are for LSIL (90-50%), HSIL (100-50%) and for total SIL (92.86-50%).
In our series, 51 of the ICC HPV Ab studied cases were resulted as HPV DNA ( Techniques of preparing thin film spreads using a liquid medium such as LBC have been developed to overcome these problems. Although these has a higher rate of satisfaction than conventional cytology in studies and the possibility of detecting HPV DNA from remaining samples, the preference of them should be discussed due to their higher cost. 10 The aim of quality in gynecological cytology is to improve the performance of the test by trying to minimize false positive and false negative results. Objective data is needed to evaluate the test performance. Sample adequacy (proportion of unsatisfactory samples), workload records, the report scales of the main categories of diagnoses for each cytopathologist and comparison with national standards, positivity rate, ASC ratio, ASC/SIL, return time, and cytology-histology compliance ratio (PPV: positive test percentage with histological confirmation of cervical dysplasia) are some of the data that can be used for this purpose.
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Workload is a determinant that affects quality parameters in gynecological cytology. The limit for the maximum number of slides that can be scanned by the scanning staff is 100 slides per workday, independent of the other tasks that can be performed by staffing. 12 In addition to the daily work load, when 7 slides/day as "ECA-adjusted workload" that uses a parameter with a higher correlation is evaluated, it means 70 slides/day with 10% ECA. 14, 15 In the study conducted by Türkmen İÇ and his colleagues, no correlation was established between the ASC / SIL rates and the workload of staff. 15 The average workload in our study is 22 slides per day.
Sample adequacy is key to quality in the cytology. It is expressed as the percentage of non-satisfactory test results in 12 month period. The technical error in the sample depends on certain aspects of the genital anatomy, sampling methods, deficiencies in description and / or inadequate training, the adequacy of sample preparation and the staining procedures. 11 Acceptable limits in Canada are reported as 0.5-2.0 %. 13 In studies performed on LBC samples, rates between 0.10 and 1.2% have been reported. 16 In our study, the non-diagnostic smear ratio was 1.9%, slightly above what was expected for LBCs.
In studies in Turkey, positivity rates in cervical cytology reported as 1.8% -8.6%. [17] [18] [19] [20] [21] [22] [23] [24] In a multicenter study that can be representative throughout Turkey, ratios that was reported by the participating centers ranged from 0. The positivity rate in our study is 3.4% (ASC-US: 1.9%, ASC-H: 0.2%, LSIL: 0.9%, HSIL: 0.1%, AGS: 0.3%, Ca: 0.01%) (Table1). The positivity rates are affected by the geographical, socio-cultural variability of the studied patient populations and the volume of cases studied; it is also expected that the values produced by the laboratory will be between the statistical intervals recommended for that region. When compared with the first 3 years in our study, the increase in LSIL rate with the partial decrease in ASCUS ratio in 2017 was statistically significant (p<0.05). We believe that this difference has emerged as a result of the ICC HPV Ab. staining which has been used for cyto-virological confirmation within the past year. ASCUS and ASC-H represent the uncertainty status. The ASCUS diagnosis has more usage potency in the study. For this reason, the ASC / SIL ratio is another parameter recommended for usage in quality control. This ratio has been reported as 1.73%-2.05% for cytologists and 0.87%-4.5% for cytotechnologists. 25 The CAP Laboratory Accreditation Program values the rates between 0.4% and 5.1% within acceptable limits. These rates have been reported by various studies published in Turkey between 2.25% and 12.6%. 15, [17] [18] [19] [20] [21] [22] [23] [24] In two separate studies that may reflect the Turkey-wide situation, the ratios are reported as 1.8% and 2.87%. 14, 17 The ASC / SIL ratio in our study is 1.89% and it is in acceptable limits.
Comparisons of gynecological cytology results with biopsy diagnoses have been a common activity in the laboratories and are required by the Clinical Laboratory Improvement Amendment (CLIA). Cytology-biopsy correlation represents a summary of many activities in the cytological detection, diagnosis and validation of cervical anomalies. No correlation can reflect; cytological screening and diagnosis problems, problems related to histological diagnosis, or clinical sampling problems occurring repeatedly as a primary cause in cytology and biopsy specimens. This monitor should not be viewed as an assessment of the performance of the cytopathology laboratory. This is an actual "system" monitor. Statistics represent the performance of all staff and processes in the acquisition, processing, and evaluation of cytology and biopsy specimens. 12 Over the last 30 years, there have been many studies on susceptibility problems in cervical cytology. Rates of SE: 61%-95% and SP: 78%-100% ratios have been reported in LBC samples. 1, 23, 27 In our study, the values of SE: 72.09%, SP: 91.28%, PPV: 62% for LSIL, the values of SE: 73.33%, SP: 100%, PPV: 100% for HSIL were obtained.
Using the HPV test as a reflex test or cytology scan can be a tool to optimize cyto-virological correlation/ screening accuracy. A high-risk HPV DNA study is generally accepted for the triage of women diagnosed with ASC-US. However, there is no consensus on the optimal management method of LSIL. 28 The HPV test should only be performed in women over 30 years of age because of the prevalence of transient infection and the low prevalence of underlying high-grade lesions. It is stated that HPV DNA testing in women under 30 may cause unnecessary evaluation and excessive treatment. In studies comparing cytology and HPV testing in Europe and North America, the sensitivity of cytology ranges from 40 to 80%, while the sensitivity of clinical-based HPV testing is consistently above 85%. The specificity of both tests shows an increase with time, but on average, cytology (96%) is more specific than the HPV test (91%). 29 In two studies conducted in Turkey, HPV positivity in patients with abnormal cytology was reported as 57% and 90.8%, respectively. This rate varies between 29%-61% in the literature. 30 In our study, HPV DNA positivity rate is 47.3%. The rate of HPV Ab detected by immunocytochemical method is 41.3%. There are no previous studies found in reference to ISC HPV Ab staining in LBC specimens. Our work reflects the first experience. The correlation between sensitivity and specificity values calculated by accepting biopsy results detected as reference values and ISC HPV Ab and HPV DNA results is statistically significant, and the contribution to morphological evaluation is promising.
Considering that cytopathologists are expert morphologists and use immunological dyes for interpretation, an immunomodulator applied in a preparation derived from LBC may be a tool for the detection of possible lesions of progression to high grade squamous intraepithelial lesions. ICC is also fast, simple and relatively inexpensive and provides information related to cytomorphology. Moreover, immunocytochemical confirmation of the molecular changes that HPV causes in host cells can be used additionally in cytological interpretation, potentially improving SE without compromising SP.
CONCLUSION
The use of cervical cytology has significantly reduced the incidence of cervical cancer. In addition to this, it is suggested that morphological interpretation should be combined with HR HPV DNA tests in women over 30 years of age, especially because they have less sensitivity for some diagnostic categories and low intra-observer repeatability rates. The data obtained in our study is close to the average values in national data. We also think that the detection of viral antibodies in the case of epithelial atypia during cytologic interpretation can provide additional evidence for morphological findings to the cytologist, improve intra-observer reproducible and interobserver compatibility, and help clinicians in managing the disease at the same time. However, we believe that this view should be supported by prospective studies because it reflects only one clinical experience.
